PMDA Publishes Its Latest Safety Notice on GLP-1 Diabetes and Weight-Loss Drugs
Japan's drug regulator PMDA has published a numbered series of safety notices for healthcare professionals that repeat important points about medicine use. The most recent entry, dated October 2026, concerns GLP-1 and GIP/GLP-1 receptor agonists, a class of diabetes and weight-loss drugs. Earlier entries cover topics such as low carnitine levels from certain antibiotics, skin reactions, and blood tests needed for specific drugs.
What does it mean?
If you are a doctor, pharmacist, or other healthcare worker, this notice reminds you how to use certain medicines more safely, including GLP-1 drugs. Patients with questions should talk to their own doctor or pharmacist rather than rely on this notice.
Who is affected?
Healthcare professionals who prescribe or dispense the medicines covered by the notice, and patients taking those medicines.